Latest Breaking News On - நாஸ்டாக் ஸ்டாக்‌ஹோல்ம் நடுவில் தொப்பி - Page 1 : comparemela.com

Orexo s flagship pharmaceutical pipeline asset OX124 enters pivotal trial

Orexo s flagship pharmaceutical pipeline asset OX124 enters pivotal trial
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Uppsala lanLena wangeIr communicationsOrexo press releaseDrug administrationDrug applicationNasdaq stockholm mid capPress release orexoPublished julyலீனா வாங்கேஈர் தகவல்தொடர்புகள்மருந்து விண்ணப்பம்நாஸ்டாக் ஸ்டாக்‌ஹோல்ம் நடுவில் தொப்பிவெளியிடப்பட்டது ஜூலை

Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia in combination with sublingual buprenorphine/ naloxone for the treatment of OUD

Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Uppsala lanLena wangeMike sumnerIr communicationsCenters for diseaseOrexo groupChief medical officerNasdaq stockholm mid capDisease controlStatistics rapid releaseDrug overdoseFirst patientலீனா வாங்கேமைக் சம்னர்ஈர் தகவல்தொடர்புகள்மையங்கள் க்கு நோய்

Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD

Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Orexo continues to strengthen ZUBSOLV´s patent portfolio with two new patents

/PRNewswire/ Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office (USPTO) has issued another two patents.

Uppsala lanLena wangeIr communicationsTrademark officeOrange bookNasdaq stockholm mid capலீனா வாங்கேஈர் தகவல்தொடர்புகள்முத்திரை அலுவலகம்ஆரஞ்சு நூல்நாஸ்டாக் ஸ்டாக்‌ஹோல்ம் நடுவில் தொப்பி

Orexo starts to test modia™ on patients in collaboration with ApexB io and Magellan Rx Management

Share this article UPPSALA, Sweden, Feb. 10, 2021 /PRNewswire/ Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the company will collaborate with ApexB.io and Magellan Rx Management to further research on the use of modia™, a digital therapeutic designed for individuals with opioid use disorder (OUD), by establishing a novel, real-world evidence approach. modia™, offers individuals with OUD access to tailored, interactive psychotherapy interventions through their mobile device or computer. This relationship will provide further data behind the need for an easily accessible digital treatment option for OUD. This is a critical time for such a treatment option as the Centers for Disease Control and Prevention (CDC) recently called for expanded efforts related to the prevention of overdose deaths during the pandemic. The US has experienced more than 83,000 deaths as a result of overdoses, an increase of 21 percent which is the highest increase recorded ever in a

United statesUppsala lanDennis urbaniakLena wangeIr communicationsCenters for diseaseMagellan health incMagellan rx managementDisease controlExecutive vice president digital therapeuticsNasdaq stockholm mid capDigital therapeuticsMagellan healthஒன்றுபட்டது மாநிலங்களில்லீனா வாங்கேஈர் தகவல்தொடர்புகள்